SGSébastien Gallien

Sébastien Gallien

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sébastien Gallien has a total of 217 co-authors. Here are the top co-authors by number of shared publications:

  • Giovanna Melica

    Infectious Diseases and Clinical Immunology Department, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94010 Créteil, France; Inserm U955 Equipe 18, 1 Rue Gustave Eiffel, 94010 Créteil, France

    5 shared publications
  • Etienne Audureau

    Université Paris-Est Créteil, Inserm, IMRB U955, Créteil, France

    3 shared publications
  • Jean-Daniel Lelièvre

    Affiliations INSERM U955, Institut Mondor de Recherche Biomédicale, Créteil, France, Université Paris Est Créteil, Faculté de Médecine, Créteil, France, Vaccine Research Institute, Créteil, France, Groupe Hospitalier Henri-Mondor Albert-Chenevier, Créteil, France

    3 shared publications
  • Slim Fourati

    IMRB INSERM U955, Team « Viruses, Hepatology, Cancer », Université Paris-Est-Créteil (UPEC) , Créteil

    3 shared publications
  • Vincent Fihman

    Bacteriology Unit - Prevention Diagnosis and Treatment of Infection Department, Henri Mondor Hospital, Créteil, France

    3 shared publications
  • Adrien Galy

    Unité Transversale de Traitement des Infections, DMU PDTI, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Faculté de Santé, Université Paris Est Créteil, F-94010 Créteil, France

    2 shared publications

Latest Publications

  • Epidemiology and outcomes of multidrug-resistant tuberculosis in Rwanda

    by J. Ntwari, R. Ndiaye, L. Mwiseneza, Y. Habimana, E. Seruyange, O. Sebatunzi, P. Migambi, Jp. Rwabihama, S. Gallien

  • National survey on aspiration pneumonia in elderly hospitalized or institutionalized patients in France in 2023

    by L. Vieilledent, T. Fraisse, G. Gavazzi, C.ROubaud Baudron, S. Diamantis, S. Gallien, Jp. Lanoix, A. Putot, V. Prendki, S. Gaujard


  • Open Access

    Reintervention for Acute Aortic Prosthesis Endocarditis: Early and Mid-Term Outcomes

    by Michele D’alonzo, Yuthiline Chabry, Giovanna Melica, Sébastien Gallien, Pascal Lim, David Aouate, Raphaëlle Huguet, Adrien Galy, Raphaël Lepeule, Vincent Fihman, et al.

    Objective: This study aimed to analyze the outcomes and challenges associated with surgical redo procedures following aortic valve replacement for acute infective endocarditis. While transcatheter aortic valve implantation is growing in terms of its utilization for degenerative bioprostheses failure, valve-in-valve procedures are limited in acute aortic endocarditis. Surgical interventions for aortic prosthesis endocarditis carry a significant risk, with a higher mortality and morbidity, often requiring concomitant complex procedures. Methods: This was a retrospective, monocentric, observational study. We identified 352 patients with infective endocarditis from the institutional database. After applying the inclusion and exclusion criteria, 54 patients who underwent surgical re-operation between 2016 and 2023 were included. Endpoints included early and late mortality, complications, and major adverse cardiac and cerebrovascular events (MACCEs). Results: From the cohort, predominantly male and with an average age of 71.9 ± 12.1 years old (79.6%), the following notable findings were derived: isolated aortic valve replacement was feasible only in 34 patients (63%) while more complex procedures were demanded in the other cases; the overall 30-day mortality rate was 18.5%, post-operative ECMO occurred in 9.3% of cases, and post-operative new stroke in 2.7%; the 5-year overall survival rate was 58.3 ± 18.6%, while freedom from MACCEs was 41.7 ± 19.7%. Another re-intervention was required in three patients during follow-up, with one case attributed to re-endocarditis. Conclusions: Despite advancements in surgical and perioperative care, redo procedures for acute infective endocarditis pose significant risks, as evidenced by the high 30-day mortality rate. However, the 5-year survival suggests a relatively acceptable outcome, underscoring the complexities and challenges inherent in managing this condition surgically.


  • Open Access

    A cluster of autochthonous dengue transmission in the Paris region – detection, epidemiology and control measures, France, October 2023

    by Nelly Fournet, Nathalie Voiry, Julian Rozenberg, Clément Bassi, Caroline Cassonnet, Anaïs Karch, Guillaume Durand, Gilda Grard, Gabriela Modenesi, Stevens-Boris Lakoussan, et al.

    A cluster of three confirmed autochthonous dengue cases was detected in October 2023 in the Val-de-Marne department neighbouring Paris, France. This marks the northernmost transmission of dengue in Europe reported to date. The epidemiological and microbiological investigations and the vector control measures are described. This event confirms the need for early case detection and response to contain dengue in Europe, especially given the 2024 Summer Olympic and Paralympic Games, when millions of visitors will visit the Greater Paris area.


  • Open Access

    Impact of a Dedicated Pretransplant Infectious Disease Consultation on Respiratory Tract Infections in Kidney Allograft Recipients: A Retrospective Study of 516 Recipients

    by Elsa Feredj, Etienne Audureau, Anna Boueilh, Vincent Fihman, Slim Fourati, Jean-Daniel Lelièvre, Sébastien Gallien, Philippe Grimbert, Marie Matignon, Giovanna Melica

    Background: Respiratory tract infections (RTIs) are a leading cause of death after kidney transplant. Preventive strategies may be implemented during a dedicated infectious disease consultation (IDC) before transplantation. Impact of IDC on RTIs after transplant has not been determined. Methods: We conducted a monocentric retrospective cohort analysis including all kidney transplant recipients from January 2015 to December 2019. We evaluated the impact of IDC on RTIs and identified risk and protective factors associated with RTIs. Results: We included 516 kidney transplant recipients. Among these, 145 had an IDC before transplant. Ninety-five patients presented 123 RTIs, including 75 (61%) with pneumonia. Patient that benefited from IDC presented significantly less RTIs (p = 0.049). RTIs were an independent risk factor of mortality (HR = 3.64 (1.97–6.73)). Independent risk factors for RTIs included HIV (OR = 3.33 (1.43–7.74)) and HCV (OR = 3.76 (1.58–8.96)). IDC was identified as an independent protective factor (OR = 0.48 (0.26–0.88)). IDC prior to transplantation is associated with diminished RTIs and is an independent protective factor. RTIs after kidney transplant are an independent risk factor of death. Implementing systematic IDC may have an important impact on reducing RTIs and related morbidity and mortality.


  • Open Access

    Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination

    by Aurélien Sokal, Paul Bastard, Pascal Chappert, Giovanna Barba-Spaeth, Slim Fourati, Alexis Vanderberghe, Pauline Lagouge-Roussey, Isabelle Meyts, Adrian Gervais, Magali Bouvier-Alias, et al.

    Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)–specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.


  • Profound Defect of Amphiregulin Secretion by Regulatory T Cells in the Gut of HIV-Treated Patients

    by Mubashira Tariq, Sébastien Gallien, Mathieu Surenaud, Aurélie Wiedemann, Francette Jean-Louis, Christine Lacabaratz, José Luis Lopez Zaragoza, Jean-David Zeitoun, Saliha Ysmail-Dalhouk, Jean-Daniel Lelièvre, et al.

    The persistence of a leaky gut in HIV-treated patients leads to chronic inflammation with increased rates of cardiovascular, liver, kidney, and neurological diseases. Tissue regulatory T (tTreg) cells are involved in the maintenance of intestinal homeostasis and wound repair through the IL-33 pathway. In this study, we investigated whether the persistence of gut mucosal injury during HIV infection might be explained in part by a flaw in the mechanisms involved in tissue repair. We observed an increased level of IL-33 in the gut of HIV-infected patients, which is associated with an increased level of fibrosis and a low peripheral reconstitution of CD4+ T cells. Our results showed that intestinal Treg cells from HIV-infected patients were enriched in tTreg cells prone to support tissue repair. However, we observed a functional defect in tTreg cells caused by the lack of amphiregulin secretion, which could contribute to the maintenance of intestinal damage. Our data suggest a mechanism by which the lack of amphiregulin secretion by tTreg may contribute to the lack of repair of the epithelial barrier. Key Points IL-33 expression is increased in the gut of HIV-infected patients. IL-33 is associated with fibrosis and low CD4+ T cell reconstitution. Despite the presence of IL-33, tTreg cells do not produce amphiregulin.


  • Open Access

    Multidisciplinary Management of Suspected Lyme Borreliosis: Clinical Features of 569 Patients, and Factors Associated with Recovery at 3 and 12 Months, a Prospective Cohort Study

    by Alice Raffetin, Julien Schemoul, Amal Chahour, Steve Nguala, Pauline Caraux-Paz, Giulia Paoletti, Anna Belkacem, Fernanda Medina, Catherine Fabre, Sébastien Gallien, et al.

    Introduction. Because patients with a suspicion of Lyme borreliosis (LB) may have experienced difficult care paths, the Tick-Borne Diseases Reference Center (TBD-RC) was started in 2017. The aim of our study was to compare the clinical features of patients according to their final diagnoses, and to determine the factors associated with recovery in the context of multidisciplinary management for suspected LB. Methods. We included all adult patients who were seen at the TBD-RC (2017–2020). Four groups were defined: (i) confirmed LB, (ii) possible LB, (iii) Post-Treatment Lyme Disease Syndrome (PTLDS) or sequelae, and (iv) other diagnoses. Their clinical evolution at 3, 6, and 9–12 months after care was compared. Factors associated with recovery at 3 and at 9–12 months were identified using logistic regression models. Results. Among the 569 patients who consulted, 72 (12.6%) had confirmed LB, 43 (7.6%) possible LB, 58 (10.2%) PTLDS/sequelae, and 396 (69.2%) another diagnosis. A favorable evolution was observed in 389/569 (68.4%) at three months and in 459/569 (80.7%) at 12 months, independent of the final diagnosis. A longer delay between the first symptoms and the first consultation at the TBD-RC (p = 0.001), the multiplicity of the diagnoses (p = 0.004), and the inappropriate prescription of long-term antibiotic therapy (p = 0.023) were negatively associated with recovery, reflecting serial misdiagnoses. Conclusions. A multidisciplinary team dedicated to suspicion of LB may achieve a more precise diagnosis and better patient-centered medical support in the adapted clinical sector with a shorter delay, enabling clinical improvement and avoiding inappropriate antimicrobial prescription.


  • Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

    by Simon B. Gressens, Slim Fourati, Anne Le Bouter, Fabien Le Bras, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Romain Gounot, Louise Roulin, Karim Belhadj, et al.